Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

NCT ID: NCT03357614

Last Updated: 2020-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1395 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-18
• Study Completion Date: 2019-12-14

Brief Summary

This is a prospective, phase 3, randomized, multicenter, double-blind, double-dummy study to compare the efficacy and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract infections (cUTI) in adults.

Conditions

Complicated Urinary Tract Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Sulopenem

Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment

Group Type: EXPERIMENTAL

Sulopenem

Intervention Type: DRUG

Antibiotic therapy for complicated UTI

Sulopenem-Etzadroxil/Probenecid

Intervention Type: DRUG

Antibiotic therapy for complicated UTI

Ertapenem

Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment

Group Type: ACTIVE_COMPARATOR

Ertapenem

Intervention Type: DRUG

Antibiotic therapy for complicated UTI

Ciprofloxacin

Intervention Type: DRUG

Antibiotic therapy for complicated UTI

Amoxicillin-clavulanate

Intervention Type: DRUG

Antibiotic therapy for complicated UTI

Interventions

Sulopenem

Antibiotic therapy for complicated UTI

Intervention Type: DRUG

Sulopenem-Etzadroxil/Probenecid

Antibiotic therapy for complicated UTI

Intervention Type: DRUG

Ertapenem

Antibiotic therapy for complicated UTI

Intervention Type: DRUG

Ciprofloxacin

Antibiotic therapy for complicated UTI

Intervention Type: DRUG

Amoxicillin-clavulanate

Antibiotic therapy for complicated UTI

Intervention Type: DRUG

Other Intervention Names

Invanz; Cipro; Augmentin

Eligibility Criteria

Inclusion Criteria

1. Adults ≥18 years of age with more than 24 hours of urinary symptoms attributable to a UTI

2. Able to provide informed consent

3. Clinically documented pyelonephritis or complicated urinary tract infection:

1. Pyelonephritis with normal anatomy

2. Complicated UTI as defined by one or more of the following factors:

i. The presence of an indwelling catheter ii. >100 mL of residual urine after voiding iii. Neurogenic bladder iv. Obstructive uropathy due to nephrolithiasis, tumor or fibrosis v. Azotemia due to intrinsic renal disease vi. Urinary retention in men possibly due to benign prostatic hypertrophy vii. Surgically modified or abnormal urinary tract anatomy

4. At least two of the following signs or symptoms:

1. Rigors, chills or fever/hypothermia

2. Flank pain or pelvic pain

3. Nausea or vomiting

4. Dysuria, urinary frequency or urinary urgency

5. Costovertebral angle tenderness on physical examination

5. A mid-stream urine specimen with:

1. a dipstick analysis positive for nitrite AND

2. evidence of pyuria as defined by either: i. a dipstick analysis positive for leukocyte esterase AND/OR ii. at least 10 white blood cells per cubic millimeter on microscopic analysis of unspun urine AND/OR iii. White blood cell count ≥10 cells/high-powered field in urine sediment

Exclusion Criteria

1. Receipt of effective antibacterial drug therapy for complicated urinary tract infection (cUTI) for a continuous duration of more than 24 hours during the previous 72 hours. Patients who have objective documentation of clinical progression of cUTI while on antibacterial drug therapy, or patients who received antibacterial drugs for surgical prophylaxis and then develop cUTI, may be appropriate for enrollment.

2. Subjects with an organism isolated from the urine within the last year known to be resistant to ertapenem

3. Severe structural or functional urinary tract abnormality responsible for an intractable infection which in the opinion of the investigator would require > 10 days of therapy or post-treatment prophylaxis (eg. patients with chronic vesiculo-ureteral reflux).

4. Uncomplicated UTI

5. Patients with paraplegia/quadriplegia

6. Hypotension with systolic blood pressure < 90 mm Hg

7. Complicated UTI associated with complete obstruction, emphysematous pyelonephritis, known or suspected renal or perinephric abscess or expected to require surgical intervention (not placement of catheters) to achieve cure

8. Patients with a known history of myasthenia gravis

9. Patients who require concomitant administration of tizanidine or valproic acid

10. Patients with a history of allergy to carbapenems or quinolones or amoxicillin-clavulanate or other beta-lactams, or hypersensitivity to probenecid

11. Renal transplantation

12. Patients requiring dialysis

13. Acute or chronic prostatitis

14. High risk for cUTI caused by Pseudomonas sp. (eg,. history of prior UTI due to Pseudomonas species, recent steroid use, others)

15. Chronic indwelling catheters or stents

16. Ileal loops or vesico-urethral reflux

17. Recent trauma to the pelvis or urinary tract within the prior 30 days

18. History of seizures

19. Patients with a history of blood dyscrasias

20. Patients with a history of uric acid kidney stones

21. Patients with acute gouty attack

22. Patients on chronic methotrexate therapy

23. Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy test result within 24 hours of study entry, are otherwise known to be pregnant, or are currently breastfeeding an infant.

24. Male subjects must agree to use of an effective barrier method of contraception during the study and for 14 days post treatment

25. Patients known to have a history of liver or kidney disease or neutropenia as defined by the following baseline laboratory criteria:

• Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 X Upper Limit of Normal
• Total bilirubin > 2 X Upper Limit of Normal
• Neutropenia (<1000 cells/mm3)

26. Patients participating in any other clinical study that involved the administration of an investigational medication

27. Patient immunocompromised

28. Patients unlikely to comply with the protocol

29. Patients considered unlikely to survive the 4-week study period or has a rapidly progressive or terminal illness

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Iterum Therapeutics, International Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Medical Facility

Bellflower, California, United States

Medical Facility

Chula Vista, California, United States

Medical Facility

La Mesa, California, United States

Medical Facility

La Palma, California, United States

Medical Facility

Torrance, California, United States

Medical Facility

Miami Lakes, Florida, United States

Medical Facility

Columbus, Georgia, United States

Medical Facility

Idaho Falls, Idaho, United States

Medical Facility

Boston, Massachusetts, United States

Medical Facility

Royal Oak, Michigan, United States

Medical Facility

Butte, Montana, United States

Medical Facility

Columbus, Ohio, United States

Medical Facility

Columbus, Ohio, United States

Medical Facility

Dallas, Texas, United States

Medical Facility

Houston, Texas, United States

Medical Facility

Kohtla-Järve, , Estonia

Medical Facility

Tallinn, , Estonia

Medical Facility

Võru, , Estonia

Medical Facility

Tbilisi, , Georgia

Medical Facility

Tbilisi, , Georgia

Medical Facility

Tbilisi, , Georgia

Medical Facility

Baja, , Hungary

Medical Facility

Budapest, , Hungary

Medical Facility

Nagykanizsa, , Hungary

Medical Facility

Nyíregyháza, , Hungary

Medical Facility

Szentes, , Hungary

Medical Facility

Tatabánya, , Hungary

Medical Facility

Daugavpils, , Latvia

Medical Facility

Liepāja, , Latvia

Medical Facility

Riga, , Latvia

Medical Facility

Riga, , Latvia

Medical Facility

Valmiera, , Latvia

Countries

United States; Estonia; Georgia; Hungary; Latvia

References

Dunne MW, Aronin SI, Das AF, Akinapelli K, Breen J, Zelasky MT, Puttagunta S. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.

Reference Type: DERIVED

PMID: 36068705 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

IT001-302

Identifier Type: -

Identifier Source: org_study_id